179
Participants
Start Date
April 4, 2022
Primary Completion Date
November 9, 2023
Study Completion Date
October 25, 2024
Atezolizumab
Atezolizumab will be administered on Day 1 of each 21-day cycle. Participants will receive atezolizumab according to their assigned route of administration (i.e., SC or IV) for the first three treatment cycles. At Cycle 4, participants will cross-over and receive atezolizumab administered according to the alternative route of administration for Cycles 4-6. This period of 3+3 cycles in both treatment arms constitutes the study Treatment Cross-over Period. After Cycle 6, participants will select how they would like atezolizumab to be administered (SC or IV) for the Treatment Continuation Period. The Treatment Continuation Period will continue until Cycle 16 for participants with early-stage NSCLC or until loss of clinical benefit, as determined by the investigator according to local standard of care, for patients with advanced NSCLC.
Clinica CIMCA, San José
ICIMED Instituto de Investigación en Ciencias Médicas, San José
Complejo Hospitalario Universitario A Coruña (CHUAC); Servicio de Oncologia, A Coruña
UPMC - Hillman Cancer Center, Pittsburgh
Instituto Europeo di Oncologia, Milan
Turun yliopistollinen keskussairaala (TYKS); Syöpäklinikka, Turku
Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid
A.O.U. Maggiore della Carità, Novara
Chungbuk National University Hospital, Cheongju-si
Tampereen yliopistollinen sairaala (TAYS); Syöpätautien poliklinikka, Tampere
Hospital Universitario de Canarias;servicio de Oncologia, San Cristóbal de La Laguna
Tri County Hematologyoncology, Canton
Hospital Clinico Universitario Lozano Blesa; Servicio de Oncologia, Zaragoza
Azienda Ospedaliera Universitaria Senese, Siena
VAASAN KESKUSSAIRAALA; Onkologian poliklinikka, Vaasa
Oulun yliopistollinen sairaala (OYS); Syöpätautien poliklinikka B, Oulu
James Lind Centro de Investigación Del Cáncer, Temuco
OrlandiOncología, Santiago
Fundacion Arturo Lopez Perez; Quimioterapia, Providencia
New Jersey Hematology Oncology Associates LLC, Brick
Asante Rogue Regional Medical Center, Medford
Fundación CENIT para la Investigación en Neurociencias, Buenos Aires
Cemic; Oncologia Clinica, Buenos Aires
Centro Oncologico Korben; Oncology, Ciudad Autonoma Buenos Aires
Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda, Ijuí
Hospital das Clinicas - UFRGS, Porto Alegre
Hospital Nossa Senhora da Conceicao, Porto Alegre
Instituto do Cancer do Estado de Sao Paulo - ICESP, São Paulo
Royal Victoria Regional Health Centre; c/o Oncology Clinical Trials, Barrie
Ottawa Hospital, Ottawa
Sault Area Hospital, Sault Ste. Marie
IRCCS Istituto Regina Elena (IFO); Oncologia Medica B, Rome
Pauls Stradins Clinical University Hospital, R?ga
Riga East Clinical University Hospital Latvian Oncology Centre, Riga
Warminsko-Mazurskie Centrum Chorób P?uc w Olsztynie; Oddzial onkologii z pododdzialem chemioterapii, Olsztyn
Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy; Oddzial III Chorob Pluc, Otwock
Asan Medical Center, Seoul
Hospital Universitari Vall d'Hebron; Oncology, Barcelona
Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia, Barcelona
Hoffmann-La Roche
INDUSTRY